Kexing Biopharm's Licensed-In Product – Liraglutide Injection Receives Marketing Approval in Peru

Article source：Nov 28,2025View： 44

Recently, another licensed-in product from Kexing Biopharm Co., Ltd. (688136.SH) - Liraglutide Injection developed by Tonghua Dongbao Pharmaceutical - has been approved for marketing by Peru's National Drug and Medical Device Agency (DIGEMID). This represents a significant breakthrough in Kexing Biopharm's overseas commercialization of diabetes medications.

As a globally recognized GLP-1 receptor agonist, liraglutide's core indication is glycemic control in patients with type 2 diabetes, and it can be used as monotherapy or in combination with other antidiabetic agents to improve blood glucose levels.

Since establishing its overseas collaboration with Tonghua Dongbao, Kexing Biopharm has actively advanced the overseas registration and GMP audits for Liraglutide Injection. In February this year, the product underwent a GMP on-site audit by the Egyptian Ministry of Health; in April, it obtained a GMP certificate from Colombia's National Food and Drug Surveillance Institute (INVIMA); and this month, it passed a GMP on-site audit by Brazil's National Health Surveillance Agency (ANVISA), a PIC/S member country. Coupled with this latest approval in Peru, Liraglutide Injection has achieved successive milestones in its global expansion, embodying the efficient collaboration and joint overseas efforts between Kexing Biopharm and Tonghua Dongbao.

In recent years, Kexing Biopharm has steadfastly pursued its "Innovation + Internationalization" strategy, deeply cultivating key overseas markets and strengthening localized marketing. Moving forward, Kexing Biopharm will continue to accelerate the overseas registration and launch of multiple products, providing high-quality, accessible therapies to patients worldwide.

About Kexing

Kexing Biopharm (Stock Code: 688136.SH) is a innovative and international biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and targeted delivery therapies.

Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.

By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.